Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: "Richard L. Schilsky" Clear advanced filters

  • The importance of appropriate patient selection necessitates novel clinical trial design and biomarker-driven trials to allow delivery of the right drug to the right patient at the right time—personalized cancer medicine. The WIN Consortium promotes collaboration between critical stakeholders and offers diverse populations of cancer patients the opportunity to participate in clinical trials with new drugs and biologics that target their tumor.

    • John Mendelsohn
    • Thomas Tursz
    • Vladimir Lazar
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 8, P: 133-134

  • This article explores some of the challenges and opportunities in developing personalized treatment for patients with cancer, which could improve outcomes, reduce toxicity, improve efficiency in drug development and help control the rising costs of cancer care.

    • Richard L. Schilsky
    Reviews
    Nature Reviews Drug Discovery
    Volume: 9, P: 363-366

  • Precision cancer medicine has the potential to dramatically improve the outcomes of patients with cancer; however, despite the precise nature of the therapies involved, generating reliable evidence of efficacy is often challenging. In this Perspective, the authors describe the challenges and potential solutions that might address the need for evidence in precision cancer medicine.

    • Jeffrey A. Moscow
    • Tito Fojo
    • Richard L. Schilsky
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 15, P: 183-192